Alpha 2.0
Login Register
» Authors » Fiona M Fleming

Fiona M Fleming

Explore the profile of Fiona M Fleming including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 36
Citations 995
Followers 0
Related Specialties
Tropical Medicine
Infectious Diseases
Parasitology
Top 10 Co-Authors
Jurg Utzinger
Penelope Vounatsou
Charles H King
Michael D French
Daniel G Colley
Amadou Garba
Alan Fenwick
Joanne P Webster
Aboulaye Meite
Susan P Montgomery
Published In
PLoS Negl Trop Dis
Parasit Vectors
Lancet Infect Dis
Am J Trop Med Hyg
Trends Parasitol
Affiliations
Soon will be listed here.
Recent Articles
1.
Risk factors associated with urogenital schistosomiasis: a multilevel assessment approach using an Oversampling Schistosomiasis Survey (SOS) community-based, Plateaux region, Togo 2022
Alidou S, Kamassa H, Lack F, Ataba E, Fleming F, Sossou E, et al.
BMJ Public Health . 2025 Feb; 3(1):e001304. PMID: 40017977
Background: Urogenital schistosomiasis is endemic in Togo. Since 2010, Togo has used preventive chemotherapy to control the disease and periodically assess its impact. This study aimed to estimate the prevalence...
2.
Female genital schistosomiasis burden and risk factors in two endemic areas in Malawi nested in the Morbidity Operational Research for Bilharziasis Implementation Decisions (MORBID) cross-sectional study
Lamberti O, Kayuni S, Kumwenda D, Ngwira B, Singh V, Moktali V, et al.
PLoS Negl Trop Dis . 2024 May; 18(5):e0012102. PMID: 38718065
Background: Female genital schistosomiasis (FGS), caused by the parasite Schistosoma haematobium (Sh), is prevalent in Sub-Saharan Africa. FGS is associated with sexual dysfunction and reproductive morbidity, and increased prevalence of...
3.
How well do coverage surveys and programmatically reported mass drug administration coverage match? Results from 214 mass drug administration campaigns in 15 countries, 2008-2017
Zoerhoff K, Mbabazi P, Gass K, Kraemer J, Fuller B, Blair L, et al.
BMJ Glob Health . 2023 May; 8(5). PMID: 37142297
Introduction: Delivering preventive chemotherapy through mass drug administration (MDA) is a central approach in controlling or eliminating several neglected tropical diseases (NTDs). Treatment coverage, a primary indicator of MDA performance,...
4.
Defining elimination as a public health problem for schistosomiasis control programmes: beyond prevalence of heavy-intensity infections
Wiegand R, Fleming F, de Vlas S, Odiere M, Kinunghi S, King C, et al.
Lancet Glob Health . 2022 Aug; 10(9):e1355-e1359. PMID: 35961358
WHO's 2021-30 road map for neglected tropical diseases (NTDs) outlines disease-specific and cross-cutting targets for the control, elimination, and eradication of NTDs in affected countries. For schistosomiasis, the criterion for...
5.
Review of 2022 WHO guidelines on the control and elimination of schistosomiasis
Lo N, Bezerra F, Colley D, Fleming F, Homeida M, Kabatereine N, et al.
Lancet Infect Dis . 2022 May; 22(11):e327-e335. PMID: 35594896
Schistosomiasis is a helminthiasis infecting approximately 250 million people worldwide. In 2001, the World Health Assembly (WHA) 54.19 resolution defined a new global strategy for control of schistosomiasis through preventive...
6.
Effect of preventive chemotherapy with praziquantel on schistosomiasis among school-aged children in sub-Saharan Africa: a spatiotemporal modelling study
Kokaliaris C, Garba A, Matuska M, Bronzan R, Colley D, Dorkenoo A, et al.
Lancet Infect Dis . 2021 Dec; 22(1):136-149. PMID: 34863336
Background: Over the past 20 years, schistosomiasis control has been scaled up. Preventive chemotherapy with praziquantel is the main intervention. We aimed to assess the effect of preventive chemotherapy on...
7.
Control and Elimination of Schistosomiasis as a Public Health Problem: Thresholds Fail to Differentiate Schistosomiasis Morbidity Prevalence in Children
Wiegand R, Evan Secor W, Fleming F, French M, King C, Montgomery S, et al.
Open Forum Infect Dis . 2021 Jul; 8(7):ofab179. PMID: 34307724
Background: Current World Health Organization guidelines utilize prevalence of heavy-intensity infections (PHIs), that is, ≥50 eggs per 10 mL of urine for and ≥400 eggs per gram of stool for...
8.
Urogenital schistosomiasis infection prevalence targets to determine elimination as a public health problem based on microhematuria prevalence in school-age children
Wiegand R, Fleming F, Straily A, Montgomery S, de Vlas S, Utzinger J, et al.
PLoS Negl Trop Dis . 2021 Jun; 15(6):e0009451. PMID: 34115760
Background: Recent research suggests that schistosomiasis targets for morbidity control and elimination as a public health problem could benefit from a reanalysis. These analyses would define evidence-based targets that control...
9.
Associations between infection intensity categories and morbidity prevalence in school-age children are much stronger for Schistosoma haematobium than for S. mansoni
Wiegand R, Evan Secor W, Fleming F, French M, King C, Deol A, et al.
PLoS Negl Trop Dis . 2021 May; 15(5):e0009444. PMID: 34033646
Background: World Health Organization (WHO) guidelines for measuring global progress in schistosomiasis control classify individuals with Schistosoma spp. infections based on the concentration of excreted eggs. We assessed the associations...
10.
Estimating true prevalence of Schistosoma mansoni from population summary measures based on the Kato-Katz diagnostic technique
Barenbold O, Garba A, Colley D, Fleming F, Assare R, Tukahebwa E, et al.
PLoS Negl Trop Dis . 2021 Apr; 15(4):e0009310. PMID: 33819266
Background: The prevalence of Schistosoma mansoni infection is usually assessed by the Kato-Katz diagnostic technique. However, Kato-Katz thick smears have low sensitivity, especially for light infections. Egg count models fitted...